wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37604501-6F7A4255-27C2-4AEA-8226-F92A43119EB3
Q37604501-6F7A4255-27C2-4AEA-8226-F92A43119EB3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37604501-6F7A4255-27C2-4AEA-8226-F92A43119EB3
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
P2860
Q37604501-6F7A4255-27C2-4AEA-8226-F92A43119EB3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37604501-6F7A4255-27C2-4AEA-8226-F92A43119EB3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f30388c170bc2d9f5f8d6741cba5d47e45c86182
P2860
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.